BSW Wealth Partners Grows Position in Danaher Co. (NYSE:DHR)

BSW Wealth Partners increased its holdings in Danaher Co. (NYSE:DHR) by 3.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,713 shares of the conglomerate’s stock after buying an additional 134 shares during the period. BSW Wealth Partners’ holdings in Danaher were worth $852,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Stonegate Investment Group LLC grew its position in shares of Danaher by 2.2% in the fourth quarter. Stonegate Investment Group LLC now owns 225,199 shares of the conglomerate’s stock valued at $51,694,000 after purchasing an additional 4,830 shares in the last quarter. VCI Wealth Management LLC grew its holdings in Danaher by 5.1% during the 4th quarter. VCI Wealth Management LLC now owns 8,422 shares of the conglomerate’s stock valued at $1,933,000 after buying an additional 406 shares in the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO increased its position in shares of Danaher by 7.6% during the fourth quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 10,550 shares of the conglomerate’s stock valued at $2,422,000 after buying an additional 743 shares during the period. Buffington Mohr McNeal lifted its holdings in shares of Danaher by 0.3% in the fourth quarter. Buffington Mohr McNeal now owns 62,954 shares of the conglomerate’s stock worth $14,451,000 after buying an additional 169 shares in the last quarter. Finally, BankPlus Wealth Management LLC purchased a new position in Danaher during the fourth quarter valued at approximately $452,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. UBS Group lowered their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen boosted their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research note on Thursday, October 31st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research note on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $285.81.

Danaher Price Performance

Shares of Danaher stock opened at $247.77 on Wednesday. The stock has a market capitalization of $178.96 billion, a P/E ratio of 47.29, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business’s 50 day simple moving average is $235.75 and its two-hundred day simple moving average is $253.65.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is currently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.